Egetis Therapeutics AB (publ)

Symbol: EGTX.ST




Market price today

  • -5.4565

    P/E Ratio

  • 0.0004

    PEG Ratio

  • 1.81B

    MRK Cap

  • 0.00%

    DIV Yield

Egetis Therapeutics AB (publ) (EGTX-ST) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Nicklas Westerholm
Full-time employees:29
Address:Klara Norra Kyrkogata 26

Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling that is in phase IIb/III clinical trial. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.

General Outlook

In simple terms, Egetis Therapeutics AB (publ) has 292.571 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep -2.638% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -5.640%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -5.680%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.430% return, is a testament to Egetis Therapeutics AB (publ)'s adeptness in optimizing resource deployment. Egetis Therapeutics AB (publ)'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.596%. Furthermore, the proficiency of Egetis Therapeutics AB (publ) in capital utilization is underscored by a remarkable -0.494% return on capital employed.

Stock Prices

Egetis Therapeutics AB (publ)'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $6.68, while its low point bottomed out at $6.4. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Egetis Therapeutics AB (publ)'s stock market.

Liquidity Ratios

Analyzing EGTX.ST liquidity ratios reveals its financial health of the firm. The current ratio of 332.92% gauges short-term asset coverage for liabilities. The quick ratio (326.95%) assesses immediate liquidity, while the cash ratio (291.92%) indicates cash reserves.

Current Ratio332.92%
Quick Ratio326.95%
Cash Ratio291.92%

Profitability Ratios

EGTX.ST profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -568.35% underscores its earnings before tax deductions. The effective tax rate stands at -0.21%, revealing its tax efficiency. The net income per EBT, 99.94%, and the EBT per EBIT, 100.77%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -564.00%, we grasp its operational profitability.

Pretax Profit Margin-568.35%
Effective Tax Rate-0.21%
Net Income per EBT99.94%
EBT per EBIT100.77%
EBIT per Revenue-564.00%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 3.33, it details the span from stock purchase to revenue. The 3 days it takes to settle debts showcases its creditor relations. Meanwhile, a 3 cash conversion cycle and 157.97% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

Days of Sales Outstanding327
Days of Inventory Outstanding1
Operating Cycle232.28
Days of Payables Outstanding50
Cash Conversion Cycle182
Receivables Turnover1.58
Payables Turnover7.29
Inventory Turnover298.86
Fixed Asset Turnover13.07
Asset Turnover0.08

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.97, and free cash flow per share, -0.97, depict cash generation on a per-share basis. The cash per share value, 1.05, showcases liquidity position. Lastly, the operating cash flow sales ratio, -4.84, offers insight into cash flow relative to sales.

Operating Cash Flow per Share-0.97
Free Cash Flow per Share-0.97
Cash per Share1.05
Operating Cash Flow Sales Ratio-4.84
Free Cash Flow to Operating Cash Flow Ratio1.00
Cash Flow Coverage Ratio-2.56
Short Term Coverage Ratio-53.56

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 14.29%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.20, we discern the balance between debt and equity financing. The long-term debt to capitalization, 15.93%, and total debt to capitalization, 16.60%, ratios shed light on its capital structure. An interest coverage of -77.21 indicates its ability to manage interest expenses.

Debt Ratio14.29%
Debt Equity Ratio0.20
Long Term Debt to Capitalization15.93%
Total Debt to Capitalization16.60%
Interest Coverage-77.21
Cash Flow to Debt Ratio-2.56
Company Equity Multiplier1.39

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.22, provides a glimpse into top-line earnings distributed across each share. Net income per share, -1.27, reflects the portion of profit attributed to each share. The book value per share, 2.13, represents the net asset value distributed per share, while the tangible book value per share, 0.53, excludes intangible assets.

Revenue Per Share0.22
Net Income Per Share-1.27
Book Value Per Share2.13
Tangible Book Value Per Share0.53
Shareholders Equity Per Share2.13
Interest Debt Per Share0.44

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 156.00%, indicates top-line expansion, while the gross profit growth, -5.58%, reveals profitability trends. EBIT growth, -61.69%, and operating income growth, -61.69%, offer insights into operational profitability progression. The net income growth, -72.51%, showcases bottom-line expansion, and the EPS growth, -29.59%, measures the growth in earnings per share.

Revenue Growth156.00%
Gross Profit Growth-5.58%
EBIT Growth-61.69%
Operating Income Growth-61.69%
Net Income Growth-72.51%
EPS Growth-29.59%
EPS Diluted Growth-28.57%
Weighted Average Shares Growth32.18%
Weighted Average Shares Diluted Growth33.86%
Operating Cash Flow Growth-60.46%
Free Cash Flow Growth-60.46%
5-Year Revenue Growth per Share-57.20%
3-Year Revenue Growth per Share-59.48%
10-Year Operating CF Growth per Share-7.36%
5-Year Operating CF Growth per Share27.33%
3-Year Operating CF Growth per Share40.85%
10-Year Net Income Growth per Share-38.48%
5-Year Net Income Growth per Share19.38%
3-Year Net Income Growth per Share47.79%
10-Year Shareholders Equity Growth per Share25.77%
5-Year Shareholders Equity Growth per Share-47.86%
3-Year Shareholders Equity Growth per Share-75.21%
Receivables Growth256.86%
Inventory Growth16.67%
Asset Growth35.48%
Book Value per Share Growth-18.46%
Debt Growth3922.22%
R&D Expense Growth41.97%
SGA Expenses Growth-100.00%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 1,237,977,727.98, captures the company's total value, considering both debt and equity. Income quality, 0.85, assesses the reliability of reported earnings.

Enterprise Value1,237,977,727.98
Income Quality0.85
Research and Development to Revenue335.94%
Intangibles to Total Assets53.83%
Stock-Based Compensation to Revenue13.89%
Graham Number7.80
Return on Tangible Assets-93.13%
Graham Net Net0.45
Working Capital242,000,000
Tangible Asset Value136,400,000
Net Current Asset Value131,300,000
Average Receivables23,300,000
Average Payables24,350,000
Average Inventory650,000
Days Sales Outstanding231
Days Payables Outstanding57
Days of Inventory On Hand1

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 3.27, and the price to book ratio, 3.27, reflect the market's valuation relative to the company's book value. The price to sales ratio, 31.50, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -6.50, and price to operating cash flows, -6.40, gauge market valuation against cash flow metrics.

Price Book Value Ratio3.27
Price to Book Ratio3.27
Price to Sales Ratio31.50
Price Cash Flow Ratio-6.40
Enterprise Value Multiple-6.28
Price Fair Value3.27
Price to Operating Cash Flow Ratio-6.40
Price to Free Cash Flows Ratio-6.50
Price to Tangible Book Ratio2.63
Enterprise Value to Sales21.49
Enterprise Value Over EBITDA-3.91
EV to Operating Cash Flow-4.45
Earnings Yield-22.82%
Free Cash Flow Yield-19.43%
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Egetis Therapeutics AB (publ) (EGTX.ST) on the STO in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -5.457 in 2024.

What is the ticker symbol of Egetis Therapeutics AB (publ) stock?

The ticker symbol of Egetis Therapeutics AB (publ) stock is EGTX.ST.

What is company IPO date?

IPO date of Egetis Therapeutics AB (publ) is 2011-04-07.

What is company current share price?

Current share price is 6.190 SEK.

What is stock market cap today?

The market cap of stock today is 1811014490.000.

What is PEG ratio in 2024?

The current 0.000 is 0.000 in 2024.

What is the number of employees in 2024?

In 2024 the company has 29.